### Sudan

**Population 2018** 42 million

<table>
<thead>
<tr>
<th>Estimates of TB burden, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>30 (21–41)</td>
<td>71 (49–98)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.97 (0.3–2)</td>
<td>2.3 (0.72–4.8)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>1.1 (0.61–1.7)</td>
<td>2.6 (1.5–4.1)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>4.6 (2.9–6.8)</td>
<td>11 (6.9–16)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.3 (0.093–0.63)</td>
<td>0.72 (0.22–1.5)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases: 2.9% (1.7–4.1)  
- Previously treated cases: 13% (8.6–17)

**TB case notifications, 2018**

- Total new and relapse: 20 117
  - % tested with rapid diagnostics at time of diagnosis: 18%
  - % with known HIV status: 34%
  - % pulmonary: 73%
  - % bacteriologically confirmed: 50%
  - % children aged 0–14 years: 10%
  - % women: 33%
  - % men: 57%

**Universal health coverage and social protection**

- **TB treatment coverage (notified/estimated incidence), 2018**: 67% (49–98)
- **TB patients facing catastrophic total costs**, 2018: 17% (9–27)
- **TB case fatality ratio (estimated mortality/estimated incidence), 2018**: 4.6 (2.9–6.8)

**TB/HIV care in new and relapse TB patients, 2018**

- Patients with known HIV status who are HIV-positive: 165 (2%)
  - on antiretroviral therapy: 159 (96%)

**Drug-resistant TB care, 2018**

- % of bacteriologically confirmed TB cases tested for rifampicin resistance: 60%
  - New cases: 20%
  - Previously treated cases: 118%
- Laboratory-confirmed cases: MDR/RR-TB: 172, XDR-TB: 0
- Patients on treatment: MDR/RR-TB: 162, XDR-TB: 0
- MDR/RR-TB cases tested for resistance to second-line drugs: 0

**Treatment success rate and cohort size**

- New and relapse cases registered in 2017: 80% (20 188)
- Previously treated cases, excluding relapse, registered in 2017: 73% (914)
- MDR/RR-TB cases started on second-line treatment in 2016: 84% (133)
- XDR-TB cases started on second-line treatment in 2016: 0%

**TB preventive treatment, 2018**

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 17% (15–18)
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 17% (15–18)

**TB financing, 2019**

- National TB budget (US$ millions): 12
- Funding source: 1% domestic, 42% international, 56% unfunded

---

© Ranges represent uncertainty intervals

º MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

ºº MDR-TB resistant to rifampicin and isoniazid; XDR-TB resistant to all first-line drugs

ººº Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2020-01-10

Data: www.who.int/tb/data